THERACRYF PLC (TCF) — Ox-1 – A deep dive into TheraCryf’s addiction programme

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Terra Grieve Investor Update regarding the Deep Dive into the Addiction Program. Throughout today's update, investors online will be in listening only mode. Please submit your questions using the Q and A tab situated on the right hand side of your screen. Just type your questions at any time and press send. Before we begin, I'd like to submit the following poll, and I'm sure that the company would be most grateful for your participation. I'd now like to hand over to your presenters today, doctor Fraser Murray and doctor Helen Coleman. Good good morning to you both. Good morning. Thank you, Mark. And, yeah, good morning to all of our existing, hopefully, new and potentially interested shareholders to THERACRYF. This sort of marks a bit of departure in the, IMCs we normally give. So instead of just presenting corporate and results based information, we're gonna have a more free flowing conversation, discussion about our Orexin program. And, hopefully, we can make this interactive. If there's anything that you're, not clear on or you'd like a bit more information on, if we're getting two signs heavy, please do pop a question into the q and a box. If we see it at the time we're talking, we'll try and address it. But if not, we will have a review of that at the end and and go through and try and address any that we can. So for those of you new to THERACRYF, I'll give a brief overview of the business, and I'll take you through the sort of schedule of discussion we have today and also allow Fraser to introduce himself who thank you very much for joining us, Fraser. He's got a lot of knowledge on this program and neuropsychiatry development space in general. So THERACRYF, we're a clinical, company focused on brain diseas...